X4 Pharmaceuticals Inc [XFOR] stock is trading at $0.70, up 1.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XFOR shares have gain 27.91% over the last week, with a monthly amount drifted -33.13%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock has seen the most recent analyst activity on December 12, 2023, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $1 from $3. On December 22, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $3 on December 12, 2022. Oppenheimer initiated its recommendation with a Outperform and recommended $20 as its price target on December 23, 2019. ROTH Capital started tracking with a Buy rating for this stock on December 18, 2019, and assigned it a price target of $20. In a note dated December 09, 2019, Citigroup upgraded an Buy rating on this stock and boosted its target price from $16 to $20.
X4 Pharmaceuticals Inc [XFOR] stock has fluctuated between $0.53 and $1.99 over the past year. Currently, Wall Street analysts expect the stock to reach $3.67 within the next 12 months. X4 Pharmaceuticals Inc [NASDAQ: XFOR] shares were valued at $0.70 at the most recent close of the market. An investor can expect a potential return of 424.29% based on the average XFOR price forecast.
Analyzing the XFOR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.15, Equity is -2.75 and Total Capital is -1.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of54.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6703 points at the first support level, and at 0.6384 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7470, and for the 2nd resistance point, it is at 0.7918.
Ratios To Look Out For
For context, X4 Pharmaceuticals Inc’s Current Ratio is 3.71. Further, the Quick Ratio stands at 3.71, while the Cash Ratio is 2.57.
Transactions by insiders
Recent insider trading involved Mostafa Adam S., Chief Financial Officer, that happened on Mar 11 ’24 when 52500.0 shares were sold. President and CEO, Ragan Paula completed a deal on Mar 11 ’24 to sell 49678.0 shares. Meanwhile, Chief Operating Officer DiBiase Mary sold 15409.0 shares on Mar 11 ’24.
